Navigation Links
Dendreon Reports First Quarter 2011 Financial Results
Date:5/2/2011

target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. DENDREON CORPORATIONCONSOLI
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
2. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
3. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
5. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
6. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
7. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
8. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
9. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
11. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage biotechnology company ... value and difficult to manufacture proteins, today announced the ... of its common stock at a price to the ... offered, 2,610,000 are being offered by Pfenex and the ... Pfenex will not receive any proceeds from the shares ...
(Date:4/24/2015)... 24, 2015 Seoul Semiconductor announced ... various applications in the lighting market. In ... of this technology in emerging markets such as ... wide range of applications such as streetlight and ... lighting. , First launched in 2005 the Acrich ...
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
(Date:4/23/2015)... April 23, 2015 WuXi PharmaTech (Cayman) Inc. ... and technology platform company serving the pharmaceutical, biotechnology and ... and the United States ... for the first quarter of 2015 after the New ... (which will be Thursday morning, May 14, 2015 Shanghai ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... Oct. ... , ... 30, 2009 -- The Boston biotechnology industry will get an early look at biotech,s future ... 2009 at Harvard Medical School. , , ,At the one-day event, recently funded companies will ...
... In its newly published Lockton Market Update ... that the markets are in a relative state of calm ... The online update includes snapshots of more than two dozen ... officers and other executives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090415/CG99351LOGO ...
... PRINCETON, N.J., Sept. 30 DOR BioPharma, Inc. (OTC Bulletin ... has completed a corporate name change from DOR BioPharma, Inc. ... of the name change, the Company,s shares of common stock ... as of today. , "We are pleased to ...
Cached Biology Technology:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Commercial Insurance Buyers Benefit From Ample Capacity 2Commercial Insurance Buyers Benefit From Ample Capacity 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... wastewater fuel cell, researchers have coaxed common bacteria to ... Logan and colleagues at Penn State University had already ... using starter material that could theoretically be sourced from ... microbes to generate hydrogen. By tweaking their design, ...
... 2007) A major study that will provide a new ... conducted by the La Jolla Institute for Allergy & ... The five-year study, funded by the National Institute of ... Institutes of Health, could lead to revolutionary new approaches ...
... Nov. 12, 2007 Visually unsettling and intellectually provocative, John ... Chervinsky, a photographer with a strong background in physics, ... Experiment in Perspective at the University of Houston at 7 ... Hoffman Hall. The event is free and open to ...
Cached Biology News:Microbes churn out hydrogen at record rate 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4Art meets science: Engineer discusses his photographs in free UH lecture 2